--- title: How Can Clinical Research Software Improve DEI for Clinical Trials? description: Find out how new technological innovations can revolutionize your approach to improving clinical trial diversity. image: https://blog.acclinate.com/hubfs/Acclinate/Blog%20Images/Clinical-Research-Software-Improve-DEI.jpg --- [![Acclinate Logo](https://blog.acclinate.com/hs-fs/hubfs/Acclinate-logo.png?width=2000&height=497&name=Acclinate-logo.png "Acclinate Logo")](https://www.acclinate.com/) - Products - [NOWINCLUDED](https://www.acclinate.com/products/nowincluded-the-community) - [eDICT](https://www.acclinate.com/products/e-dict) - Solutions - [Pharmaceutical Companies](https://www.acclinate.com/solutions/for-pharmaceutical-companies) - [Contract Research Organizations](https://www.acclinate.com/solutions/for-cros) - [Partners](https://www.acclinate.com/solutions/community-partners) - Company - [About Us](https://www.acclinate.com/about) - [Careers](https://www.acclinate.com/careers) - [News](https://news.acclinate.com) - Resources - [Resource Library](https://www.acclinate.com/resources) - [Blog](https://blog.acclinate.com) - [Press Kit](https://www.acclinate.com/press-kit) - [Events](https://www.acclinate.com/events) - [Glossary](https://www.acclinate.com/glossary) - [FAQ](https://www.acclinate.com/faq) - [Talk to Our Team](https://info.acclinate.com/get-in-touch) [![Talk to Our Team](https://no-cache.hubspot.com/cta/default/19943632/2e1c34dc-aaa1-43b8-b5f4-469b0db4e302.png)](https://cta-redirect.hubspot.com/cta/redirect/19943632/2e1c34dc-aaa1-43b8-b5f4-469b0db4e302) [![Acclinate Logo](https://blog.acclinate.com/hs-fs/hubfs/Acclinate_Logo.png?width=500&height=149&name=Acclinate_Logo.png "Acclinate Logo")](https://www.acclinate.com/) - Products - [**NOWINCLUDED**Acclinate’s B2C community platform ](https://www.acclinate.com/products/nowincluded-the-community) - [**e-DICT**Acclinate’s patented AI-powered technology ](https://www.acclinate.com/products/e-dict) - Solutions - [**Pharmaceutical Companies**Community-driven recruitment and real-world insights to support diverse, compliant clinical trials. ](https://www.acclinate.com/solutions/for-pharmaceutical-companies) - [**Contract Research Organization (CRO)**Scalable patient engagement and recruitment solutions that reduce risk and improve enrollment timelines. ](https://www.acclinate.com/solutions/for-cros) - [**Partners**Trusted partnerships that connect research opportunities with the communities they aim to serve. ](https://www.acclinate.com/solutions/community-partners) - Company - [**About us**We help clinical research teams reach diverse communities, build trust, and improve trial participation. ](https://www.acclinate.com/about) - [**Careers**Join a mission-driven team advancing inclusive clinical research and community-powered health innovation. ](https://www.acclinate.com/careers) - Resources - [**Resources Hub** ](https://www.acclinate.com/resources) - [**Glossary** ](https://www.acclinate.com/glossary) - [**Press Kit** ](https://www.acclinate.com/press-kit) - [**Events** ](https://www.acclinate.com/events) - [**Blog** ](https://blog.acclinate.com/) - [**News** ](https://news.acclinate.com/) - [![](https://cdn.prod.website-files.com/695fbca039298e2117988a78/69e7b588548c7ad7bd8ab0bc_9dd915489696393dc63d7785ee2e52c7_Question%20mark%20image.png) **FAQs** ](https://www.acclinate.com/faq) - [ Contact Us ](https://www.acclinate.com/contact-us) Stay up to date Get news directly in your inbox Topic All - [Affective Trust ](https://blog.acclinate.com/tag/affective-trust) - [Announcement ](https://blog.acclinate.com/tag/announcement) - [Clinical Research Software ](https://blog.acclinate.com/tag/clinical-research-software) - [Clinical Trial Recruitment Strategies ](https://blog.acclinate.com/tag/clinical-trial-recruitment-strategies) - [Community ](https://blog.acclinate.com/tag/community) - [Diversity in Clinical Trials ](https://blog.acclinate.com/tag/diversity-in-clinical-trials) - [e-DICT™ ](https://blog.acclinate.com/tag/e-dict) - [FDA Diversity Plan ](https://blog.acclinate.com/tag/fda-diversity-plan) - [FDA Guidance: Diversity in Clinical Trials ](https://blog.acclinate.com/tag/fda-guidance-diversity-in-clinical-trials) - [Health Equity ](https://blog.acclinate.com/tag/health-equity) - [Partnerships ](https://blog.acclinate.com/tag/partnerships) - [Representation in Healthcare ](https://blog.acclinate.com/tag/representation-in-healthcare) [Diversity in Clinical Trials](https://blog.acclinate.com/topic/diversity-in-clinical-trials) [Health Equity](https://blog.acclinate.com/topic/health-equity) # How Can Clinical Research Software Improve DEI for Clinical Trials? Find out how new technological innovations can revolutionize your approach to improving clinical trial diversity. ![doctor using laptop computer](https://blog.acclinate.com/hubfs/Acclinate/Blog%20Images/Clinical-Research-Software-Improve-DEI.jpg) Clinical Trial Diversity: What Does It Really Mean? Clinical trials are critical for evaluating the safety and effectiveness of medical devices and pharmaceutical products. The results of trials guide t... Read More ![ Acclinate](https://blog.acclinate.com/hubfs/69b96486c4b036c19f462c19_acclinate-logo.png) [Acclinate](https://blog.acclinate.com/author/acclinate) Acclinate turns trust and data into better representation. Share this Post: [**](https://www.facebook.com/sharer/sharer.php?u=https://blog.acclinate.com/how-can-clinical-research-software-improve-dei-for-clinical-trials) [**](https://twitter.com/home?status=https://blog.acclinate.com/how-can-clinical-research-software-improve-dei-for-clinical-trials) [** ](https://www.linkedin.com/shareArticle?mini=true&url=https://blog.acclinate.com/how-can-clinical-research-software-improve-dei-for-clinical-trials&title=How%20Can%20Clinical%20Research%20Software%20Improve%20DEI%20for%20Clinical%20Trials) Stay up to date Get news directly in your inbox Though the life sciences industry has committed to improving diversity in clinical trials, there’s still work to be done. Childhood asthma is a case in point. *Clinical Leader* [noted](https://www.clinicalleader.com/doc/two-straightforward-ways-to-improve-de-i-in-clinical-trials-0001) the widely prescribed asthma drug albuterol, approved by the U.S. Food and Drug Administration (FDA) more than 20 years ago, still performs poorly in children of African and Puerto Rican ancestry. Asthma is prevalent in these populations, but researchers haven’t conducted many trials in communities of color. As a result, the reasons for the drug’s ineffectiveness aren’t clear, and alternatives haven’t yet been identified.   Fortunately, advances in clinical research software are helping researchers analyze digital engagement efforts. Bryan Saxon, Head of Product and Technology for Acclinate, explains that these types of tools offer sponsors two important benefits. One is identifying those who might be most willing to participate in a trial based on how they engage with content online. The other is determining which content drives the most engagement, which is an important step in [building affective trust](https://blog.acclinate.com/overcome-clinical-trial-recruitment-challenges-start-with-affective-trust) with communities underrepresented in clinical trials.  [![Download Now – Increasing Diversity in Clinical Trials: A Comprehensive Guide for Pharma Companies](https://no-cache.hubspot.com/cta/default/19943632/interactive-169988622868.png) ](https://blog.acclinate.com/hs/cta/wi/redirect?encryptedPayload=AVxigLLzQ3VEXSZaZQmGHJO66ohj3hs4zJyPRFZJHjpIn7Gy9w7WY3ppCbUdmqwXOW63xpqRN4Y%2FwYWf7Ppyph6BIfysjg1aQ5q344zTHc%2FDZU%2Fbe9U0hP8P9bbnhnL7iAptG%2BpowsUjRrtPMyvyEq6ZAJ8Y5uWC%2F%2FufG%2F2WafYRVWOkwIBG3xct%2BX2vlRU8ilSrNmUTHrWJ%2BRdtyrScYfmc1uuvXA8ac59GCPuL1g%3D%3D&webInteractiveContentId=169988622868&portalId=19943632) ## **Open a “window” to ****clinical research analytics**  Clinical researchers are taking multiple steps to make trials more diverse, including the FDA Draft Guidance, backed by mandatory FDORA requirements. Other health equity solutions, as [detailed](https://www.pharmavoice.com/news/pharma-diversity-DEI-clinical-trial-BIO-GSK/654057/) by PharmaVoice, include internal diversity scorecards and community-based partnerships.   Targeted outreach to communities of color is another important step. This can happen in-person or across multiple channels, like engaging with a social media post, watching a video, reading an email or text message, joining a disease-specific online community (like Acclinate’s [NOWINCLUDED](http://www.nowincluded.com/)), and so on. For researchers, the goal is to get individuals who engage with content to complete a prescreening questionnaire and see if they meet inclusion criteria for a clinical trial.  Saxon’s work focuses on e-DICT™, Acclinate's analytics platform, providing real-time reporting on community access and engagement activities and insights into potential clinical trial participants. He describes the tool as “a window into the work” sponsors do to communicate about clinical trial opportunities. The clinical research analytics tool has three important functions.  1. Aggregate data from in-person and omnichannel community engagement activity. Otherwise, data about interactions such as videos, social media posts, and emails must be collected and formatted manually from disparate platforms. That takes time and slows down the engagement process.  2. Display the results of engagement efforts. Along with drilling down to an individual level, e-DICT™ lets sponsors see which content worked well and which fell flat. Pulling in qualitative insights from sponsor sites, such as barriers to achieving enrollment goals, provides additional context and further helps researchers more effectively connect with communities.   3. Assign an individual a participation probability index (PPI) using a proprietary algorithm. Saxon explains that this is a crucial benefit of Acclinate’s e-DICT™ clinical research software. It helps Acclinate inform sponsors of those who are willing to participate, those who are unsure, and those who are not yet ready – to inform researchers of the next steps and help them to achieve a more strategic, data-driven approach. “We create more of a [funnel] so that researchers more readily know who's willing to participate, and then it's less about trying to get 1,000,000 people to get one participant,” Saxon says. In other words, e-DICT™'s proprietary PPI score is an efficiency enabler.  ## **Clinical research software****’s far-reaching impact**  Recently, *pharmaphorum* [outlined](https://pharmaphorum.com/r-d/can-technology-help-diversify-clinical-trials) several ways technology can increase access to and diversity in clinical trials, including faster patient assessments and additional accommodation for remote participants. This is certainly helpful – but it skips the important step of identifying, engaging, and mobilizing trial participants from communities of color in the first place.  The insights available from clinical trial software such as e-DICT™ empower organizations to not just execute but also plan more diverse trials. Sponsors can see which population subsets in which geographic areas may be willing to participate in a trial, along with which content is most likely to resonate with individuals in that population. The impact of a more diverse clinical trial population is far-reaching. For starters, it specifically addresses the FDA’s diversity action plan requirements, without which the FDA may conduct additional reviews or request further studies, delaying a drug’s approval or perhaps even jeopardizing it. [Research](https://bmjopen.bmj.com/content/10/6/e038863.full) has shown additional trials, coupled with additional clinic visits, contribute to significant increases in drug development costs, not to mention further delays in bringing treatments to market.  In addition, diverse trial populations let researchers gain direct evidence of how treatments affect traditionally underrepresented populations. For communities of color who face higher disease prevalence for asthma and Type 2 diabetes, obesity, and certain cancers, this is vital to improving clinical outcomes and addressing longstanding barriers to health equity.  ## **Maximize ****health equity solutions**** by leading with affective trust **  [NOWINCLUDED,](https://nowincluded.com/multiple-myeloma/) the community engagement arm of Acclinate, engages people of color both digitally and in-person to build relationships with supportive communities while also learning about the clinical trials and health resources available to them. NOWINCLUDED is built on the foundation of [Acclinate’s Affective Trust Framework](https://blog.acclinate.com/clinical-trial-diversity-an-affective-trust-framework-for-engaging-recruiting-communities-of-color), a set of principles for leveraging technology and other health equity solutions to [build trusting relationships](https://blog.acclinate.com/overcome-clinical-trial-recruitment-challenges-start-with-affective-trust) with people of color – based on authenticity and inclusivity.  The clinical trial software features available through e-DICT™ align with this framework. By analyzing the probability that individuals will be willing to participate in the trial with a PPI score and identifying the types of activities that resonate with individuals likely to participate, researchers are equipped to be more strategic outreach and meet their goals for clinical trial diversity faster and with more efficiency.  Boost inclusivity in trials faster and for the long term by zeroing in on the populations you lack. Acclinate gives you access to communities of color, facilitates engagement around your trials, then analyzes the data generated to predict and plan where and when your next effort should happen to create the ongoing representation you need. To learn more, [schedule a 1:1 Meeting](https://www.acclinate.com/request-a-demo).  [![Increasing Diversity in Clinical Trials](https://no-cache.hubspot.com/cta/default/19943632/interactive-170609956904.png) ](https://blog.acclinate.com/hs/cta/wi/redirect?encryptedPayload=AVxigLJGKuXvgIHsMRytC6MtfaIbxwuK9wJxnnQ7hciNSOqGkGydmXceE6QdAX1cHAT2pfMAI8vUqPFWofx1ijj0P1%2Bl%2B%2F7CRNdeB0aH4d8b3NhR4WedKQ8C2%2BroMevuROwkiBXQUQQm64e3snYad9ayKl4u9nnTa9hiJW6V%2FiqrXAakTGENHlhmOCc8B%2F73htcPBwLHLQ49VZSJqOuCSse4r6ZsithoORT06U19NA%3D%3D&webInteractiveContentId=170609956904&portalId=19943632) ## Recent Posts [![Clinical Trial Management: The Hidden Risk of Homogeneous Trials in a One-Pivotal-Study World](https://blog.acclinate.com/hubfs/mature-female-patient-at-doctors-appointment-2026-01-08-06-10-47-utc.webp) ](https://blog.acclinate.com/clinical-trial-management-the-hidden-risk-of-homogeneous-trials-in-a-one-pivotal-study-world) [- [Diversity in Clinical Trials](https://blog.acclinate.com/news/tag/diversity-in-clinical-trials) ](https://blog.acclinate.com/clinical-trial-management-the-hidden-risk-of-homogeneous-trials-in-a-one-pivotal-study-world) [ Clinical Trial Management: The Hidden Risk of Homogeneous Trials in a One-Pivotal-Study World ](https://blog.acclinate.com/clinical-trial-management-the-hidden-risk-of-homogeneous-trials-in-a-one-pivotal-study-world) June 25, 2026 3 Min Read Drug development economics are changing. Sponsors are increasingly relying on a single pivotal trial to support approval. Though the goal of this appr... Read More [![Clinical Trial Generalizability: What Regulators Will Scrutinize Next](https://blog.acclinate.com/hubfs/woman-visiting-dermatologist-2026-01-08-22-23-31-utc.webp) ](https://blog.acclinate.com/clinical-trial-generalizability-what-regulators-will-scrutinize-next) [- [Diversity in Clinical Trials](https://blog.acclinate.com/news/tag/diversity-in-clinical-trials) ](https://blog.acclinate.com/clinical-trial-generalizability-what-regulators-will-scrutinize-next) [ Clinical Trial Generalizability: What Regulators Will Scrutinize Next ](https://blog.acclinate.com/clinical-trial-generalizability-what-regulators-will-scrutinize-next) June 25, 2026 3 Min Read For years, generalizability was framed as a methodological concern. Reviewers debated whether results could reasonably extend beyond a trial’s enrolle... Read More [![Site Engagement Index (SEI): Measuring What Actually Builds Trust](https://blog.acclinate.com/hubfs/computer-screen-trading-and-back-with-charts-hom-2026-01-09-09-28-19-utc.webp) ](https://blog.acclinate.com/site-engagement-index-sei-measuring-what-actually-builds-trust) [- [Clinical Research Software](https://blog.acclinate.com/news/tag/clinical-research-software) ](https://blog.acclinate.com/site-engagement-index-sei-measuring-what-actually-builds-trust) [ Site Engagement Index (SEI): Measuring What Actually Builds Trust ](https://blog.acclinate.com/site-engagement-index-sei-measuring-what-actually-builds-trust) June 25, 2026 3 Min Read Clinical research lacks anything but metrics. Enrollment targets, site activation timelines, and digital engagement rates are tracked closely across s... Read More [![](https://blog.acclinate.com/hubfs/Imported_Blog_Media/6567a9f90c0cf111067913e2_Merck%20Pop%20Up2.png) ](https://blog.acclinate.com/acclinate-collaborates-with-merck-to-increase-clinical-trial-diversity) [ Acclinate to support Merck's oncology clinical trials ](https://blog.acclinate.com/acclinate-collaborates-with-merck-to-increase-clinical-trial-diversity) June 24, 2026 1 Min Read Acclinate, an expert in health equity through inclusive research, is collaborating with Merck, known as MSD outside the United States and Canada, to h... Read More [![Why Trial Diversity Is Now a Risk Management Strategy](https://blog.acclinate.com/hubfs/Why-Trial-Diversity-Is-Now-a-Risk-Management-Strategy.jpg) ](https://blog.acclinate.com/why-trial-diversity-is-now-a-risk-management-strategy) [- [Diversity in Clinical Trials](https://blog.acclinate.com/news/tag/diversity-in-clinical-trials) ](https://blog.acclinate.com/why-trial-diversity-is-now-a-risk-management-strategy) [ The New Control Lever: Why Trial Diversity Is Now a Risk Management Strategy ](https://blog.acclinate.com/why-trial-diversity-is-now-a-risk-management-strategy) March 2, 2026 3 Min Read For years, conversations around trial diversity were framed as ethical or reputational concerns. That framing no longer reflects regulatory reality. Read More [![Acclinate’s NOWINCLUDED: Turning Community Insights Into Research Equity](https://blog.acclinate.com/hubfs/AdobeStock_470269560.webp) ](https://blog.acclinate.com/acclinates-nowincluded-turning-community-insights-into-research-equity) [- [Community](https://blog.acclinate.com/news/tag/community) ](https://blog.acclinate.com/acclinates-nowincluded-turning-community-insights-into-research-equity) [ Acclinate’s NOWINCLUDED: Turning Community Insights Into Research Equity ](https://blog.acclinate.com/acclinates-nowincluded-turning-community-insights-into-research-equity) February 16, 2026 3 Min Read Clinical research equity efforts originate with good intentions. But they often hit a roadblock in practice: communities are asked to participate in h... Read More [![How Acclinate’s e-DICT™ Technology Builds Real-Time Community Trust](https://blog.acclinate.com/hubfs/AdobeStock_1631551849.webp) ](https://blog.acclinate.com/how-acclinates-e-dict-technology-builds-real-time-community-trust) [- [Community](https://blog.acclinate.com/news/tag/community) ](https://blog.acclinate.com/how-acclinates-e-dict-technology-builds-real-time-community-trust) [ How Acclinate’s e-DICT™ Technology Builds Real-Time Community Trust ](https://blog.acclinate.com/how-acclinates-e-dict-technology-builds-real-time-community-trust) February 9, 2026 3 Min Read Reaching underrepresented communities in healthcare research has never been simple. Participation decisions are shaped by lived experience, historical... Read More [![Data-Driven Inclusion](https://blog.acclinate.com/hubfs/Acclinate/Blog%20Images/Acclinate-Data-Driven-Inclusion.jpg) ](https://blog.acclinate.com/data-driven-inclusion-predictive-analytics-for-trial-enrollment) [- [Clinical Research Software](https://blog.acclinate.com/news/tag/clinical-research-software) ](https://blog.acclinate.com/data-driven-inclusion-predictive-analytics-for-trial-enrollment) [ Data-Driven Inclusion: Predictive Analytics for Trial Enrollment ](https://blog.acclinate.com/data-driven-inclusion-predictive-analytics-for-trial-enrollment) February 2, 2026 2 Min Read Subpar enrollment remains one of the most common causes of trial delays. But sponsors often miss a key factor: underrepresentation. Lack of diversity ... Read More [![Exploring Diversity in Clinical Research With Acclinate](https://blog.acclinate.com/hubfs/Acclinate/Blog%20Images/Exploring-Diversity-in-Clinical-Research-With-Acclinate.jpg) ](https://blog.acclinate.com/exploring-diversity-in-clinical-research-with-acclinate) [- [Diversity in Clinical Trials](https://blog.acclinate.com/news/tag/diversity-in-clinical-trials) ](https://blog.acclinate.com/exploring-diversity-in-clinical-research-with-acclinate) [ Exploring Diversity in Clinical Research With Acclinate ](https://blog.acclinate.com/exploring-diversity-in-clinical-research-with-acclinate) January 26, 2026 3 Min Read Diversity in clinical research remains a widely discussed goal, yet progress has been uneven. Trials still grapple with subpar representation, limited... Read More [![Clinical Trial Management: The Hidden Risk of Homogeneous Trials in a One-Pivotal-Study World](https://blog.acclinate.com/hubfs/mature-female-patient-at-doctors-appointment-2026-01-08-06-10-47-utc.webp) June 25, 2026 Clinical Trial Management: The Hidden Risk of Homogeneous Trials in a One-Pivotal-Study World Read More ](https://blog.acclinate.com/clinical-trial-management-the-hidden-risk-of-homogeneous-trials-in-a-one-pivotal-study-world) [![Clinical Trial Generalizability: What Regulators Will Scrutinize Next](https://blog.acclinate.com/hubfs/woman-visiting-dermatologist-2026-01-08-22-23-31-utc.webp) June 25, 2026 Clinical Trial Generalizability: What Regulators Will Scrutinize Next Read More ](https://blog.acclinate.com/clinical-trial-generalizability-what-regulators-will-scrutinize-next) [![Site Engagement Index (SEI): Measuring What Actually Builds Trust](https://blog.acclinate.com/hubfs/computer-screen-trading-and-back-with-charts-hom-2026-01-09-09-28-19-utc.webp) June 25, 2026 Site Engagement Index (SEI): Measuring What Actually Builds Trust Read More ](https://blog.acclinate.com/site-engagement-index-sei-measuring-what-actually-builds-trust) ![Woman wearing Acclinate Shirt](https://blog.acclinate.com/hs-fs/hubfs/layer1_image.webp?width=1600&height=1068&name=layer1_image.webp) ![Medical Research Software e-DICT](https://blog.acclinate.com/hs-fs/hubfs/layer2_image.webp?width=885&height=885&name=layer2_image.webp) ![layer2.2_image](https://blog.acclinate.com/hs-fs/hubfs/layer2.2_image.webp?width=1505&height=1197&name=layer2.2_image.webp) ![layer3_image](https://blog.acclinate.com/hs-fs/hubfs/layer3_image.webp?width=1600&height=1067&name=layer3_image.webp) ## Ready to Measure Your True Impact? Partner with Acclinate to turn mission into measurable, data-driven action. [ Get Started ](https://www.acclinate.com/contact-us) [![Acclinate Logo Reversed](https://blog.acclinate.com/hs-fs/hubfs/footer_logo.png?width=1600&height=398&name=footer_logo.png "Acclinate Logo Reversed")](https://www.acclinate.com/) - Products - [NOWINCLUDED](https://www.acclinate.com/products/nowincluded-the-community) - [e-DICT](https://www.acclinate.com/products/e-dict) - Solutions - [Pharmaceutical Companies](https://www.acclinate.com/solutions/for-pharmaceutical-companies) - [CROs](https://www.acclinate.com/solutions/for-cros) - [Community Partners](https://www.acclinate.com/solutions/community-partners) - Resources - [Resources Hub](https://www.acclinate.com/resources) - [Glossary](https://www.acclinate.com/glossary) - [Press Kit](https://www.acclinate.com/press-kit) - [Events](https://www.acclinate.com/events) - [News](https://news.acclinate.com/) - [Blog](https://blog.acclinate.com/) - [FAQs](https://www.acclinate.com/faq) - Company - [About us](https://www.acclinate.com/about) - [Careers](https://www.acclinate.com/careers) - [Contact Us](https://www.acclinate.com/contact-us) - Follow Us - [** Linkedin](https://www.linkedin.com/company/acclinateinc/) - [Privacy Policy](https://www.acclinate.com/privacy) - [Terms of Service](https://www.acclinate.com/terms-of-use-acclinate) ```json { "@context" : "https://schema.org", "@type" : "BlogPosting", "author" : { "@type" : "Person", "name" : "Acclinate", "url" : "https://blog.acclinate.com/author/acclinate" }, "dateModified" : "2026-06-18T19:32:32.477Z", "datePublished" : "2024-04-25T17:00:00.000Z", "headline" : "How Can Clinical Research Software Improve DEI for Clinical Trials?", "image" : [ "https://blog.acclinate.com/hubfs/Acclinate/Blog%20Images/Clinical-Research-Software-Improve-DEI.jpg" ], "mainEntityOfPage" : { "@id" : "https://blog.acclinate.com/how-can-clinical-research-software-improve-dei-for-clinical-trials", "@type" : "WebPage" }, "publisher" : { "@type" : "Organization", "logo" : { "@type" : "ImageObject", "url" : "https://blog.acclinate.com/hubfs/Acclinate-logo.png" }, "name" : "Acclinate" } } ```